Advancing Antibody Fragment-Lipid Conjugates for Greater Therapeutic Targeting
Time: 11:30 am
day: Conference Day 2
Details:
- Explore the development of antibody fragment-lipid conjugates, which utilise antibody fragments instead of full antibodies to create specialised lipid formulations. This flexibility allows for mix-and-match combinations tailored to specific therapeutic needs
- Review the current pipeline, including the trastuzumab Fab-lipid conjugate TL01 and several different product formats under development based on it
- Delve into the creation of multi-specific antibody conjugated liposomes. Highlight the unique mechanism of the liposomal T-cell engager and immune modulator under development, and potential benefits of the lipid carriers in cancer immunotherapy
